Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)


Lenalidomide and Intensive Chemotherapy for Patients with Higher-Risk MDS or AML with Del(5q)
Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with B Douglas Smith, MD (1/4/11)
Ades L et al. Lenalidomide (LEN) combined to intensive chemotherapy (IC) in AML and higher risk MDS with del 5q. Results of a phase I/II study of the Groupe Francophone des Myelodysplasies (GFM). Proc ASH 2010;Abstract 508.

Dr Smith is Associate Professor of Oncology at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland.